Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: alex gurion who wrote (213)	1/12/1998 2:19:00 PM
From: alex gurion	Respond to of 783

Here is the article: January 12, 1998 Biochem Pharma Puts '97 Net At More Than 70c/Shr Dow Jones Newswires By Mark Boslet SAN FRANCISCO (Dow Jones)--BioChem Pharma Inc. (BCHE) will have 1997 earnings of more than 70 cents a share, Chief Executive Francesco Bellini said. Speaking at the Hambrecht & Quist Healthcare Conference, Bellini also said 1997 worldwide sales of the company's AIDS-fighting drug 3TC would be "slightly in excess of $700 million." After his presentation, he added that BioChem Pharma is comfortable with a 1998 earnings range of $1.05 to $1.15 a share. During his address, Bellini said markets for 3TC will grow in 1998, especially in the U.S. and Europe, and especially in the second half of the year when new, better-tolerated AIDS fighting agents will come out. The introduction of new drugs inevitably expands the overall market, he said. "We don't see competitors for 3TC for the time being," he added. BioChem Pharma also expects several approvals for use of its Hepatitis B-fighting drug Lamivudine in 1998, but Bellini didn't specify from which countries. Filings seeking approval in the U.S. and Europe will be made before July, he said. Meanwhile, the company expects its pain-fighting drug BCH 3963 to begin phase 1 clinical trials in Europe in the first quarter. Bellini went on to say the company would report record revenue for 1997, and expects another record for 1998. -Mark Boslet; 415-496-1366